Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 545.10, up by 11.95 points or 2.24% from its previous closing of Rs. 533.15 on the BSE.

The scrip opened at Rs. 549.95 and has touched a high and low of Rs. 551.40 and Rs. 545.00 respectively. So far 54,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 854.50 on 04-Aug-2016 and a 52 week low of Rs. 493.00 on 29-May-2017.

Last one week high and low of the scrip stood at Rs. 551.40 and Rs. 505.45 respectively. The current market cap of the company is Rs. 1,31,106.00 crore.

The promoters holding in the company stood at 54.39%, while Institutions and Non-Institutions held 33.49% and 12.13% respectively.

Sun Pharmaceutical Industries’ one of the wholly owned subsidiaries has received final approval from USFDA for its Abbreviated New Drug Application (ANDA) for generic version of Zetia, (ezetimibe) Tablets 10mg. These generic ezetimibe tablets are therapeutic equivalents of Merck’s Zetia tablets. As per IMS, ezetimibe tablets had annual sales of approximately $2.7 billion in the US for the 12 months ended April 2017.

Sun Pharmaceutical Industries is an Indian multinational pharmaceutical company that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States.